Emily Randall
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
3 flagsRep. Randall sold $1K-$15K in $AMGN (Amgen) on Jan 6, 2025 — 3 days before the Skinny Labels, Big Savings Act (S43) was introduced, a bill that creates a safe harbor for generic drug manufacturers and is bearish for branded drug makers.
Rep. Randall sold $1K-$15K in $XOM (Exxon Mobil) on Jan 6, 2025 — 30 days before the No Tax Breaks for Outsourcing Act (S409) was introduced, a bill that increases taxes on foreign profits and is bearish for multinational oil companies. On the same day, she also sold $1K-$15K in $PG (Procter & Gamble), which faces similar tax implications from the same bill.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| SELL | $ABT | Abbott Laboratories Common Stock (ABT) [ST] | $1K-$15K | — | $93.86 | — | Jan 6, 2025 |
| PARTIAL SELL | $GOOG | Alphabet Inc. - Class C Capital Stock (GOOG) [ST] | $1K-$15K | — | — | — | Jan 7, 2025 |
| SELL | $AMGN | Amgen Inc. - Common Stock (AMGN) [ST] | $1K-$15K | — | — | — | Jan 6, 2025 |
| SELL | $XOM | Exxon Mobil Corporation Common Stock (XOM) [ST] | $1K-$15K | — | — | — | Jan 6, 2025 |
| SELL | $FTV | Fortive Corporation Common Stock (FTV) [ST] | $1K-$15K | — | — | — | Jan 6, 2025 |
| SELL | $MDT | Medtronic plc. Ordinary Shares (MDT) [ST] | $1K-$15K | — | $81.90 | — | Jan 6, 2025 |
| SELL | $MDLZ | Mondelez International, Inc. - Class A Common Stock (MDLZ) [ST] | $1K-$15K | — | — | — | Jan 6, 2025 |
| SELL | $PEP | Pepsico, Inc. (PEP) [ST] | $1K-$15K | — | — | — | Jan 6, 2025 |
| SELL | $PG | Procter & Gamble Company (PG) [ST] | $1K-$15K | — | — | — | Jan 6, 2025 |
| SELL | $VZ | Verizon Communications Inc. Common Stock (VZ) [ST] | $1K-$15K | — | — | — | Jan 6, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Expanding Child Care Access Act of 2025
HR 1296 proposes a $5,000 refundable tax credit for home-based child care providers' startup expenses, including diapers, toys, and learning materials. The bill is in early stages (referred to Ways & Means, 39 cosponsors), but if enacted, it would directly subsidize demand for PG, KMB, MAT, and HAS consumer products. Market data shows these stocks are flat to slightly down over 30 days, reflecting no current premium for this potential catalyst.
No Tax Breaks for Outsourcing Act
The No Tax Breaks for Outsourcing Act (S409) would eliminate tax deferral on foreign profits for U.S. multinationals, increasing effective tax rates by 5-8 percentage points. The bill is in early stages (referred to Senate Finance Committee, 19 cosponsors) and poses a 4-8% annual net income headwind for high international-exposure companies. Despite 8-30% rallies in the last 30 days across MSFT, AAPL, GOOGL, KO, PG, XOM, and CVX, this legislative risk is not currently priced into valuations.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
Offshore Energy Security Act of 2025
S. 109 mandates 20 Gulf of Mexico lease sales over 10 years, locking in a predictable offshore drilling schedule. The bill is in early legislative stages, reducing near-term probability, but its passage would structurally benefit pure-play Gulf operators like Occidental, Chevron, and ExxonMobil by removing regulatory uncertainty. Market data shows a broad 7-day energy sector bounce with OXY leading at +5.07%, but the 30-day trend remains deeply negative (-8.27% for OXY, -9.8% for XOM) indicating the sector is pricing in headwinds beyond this bill.
Defending Domestic Orange Juice Production Act of 2025
HR933 proposes reducing the FDA standard for orange juice soluble solids from 10.5% to 10.0%, a direct regulatory cost savings for major OJ producers. The bill is early-stage but has strong bipartisan Florida delegation support with 25 cosponsors. $KO, $PEP, and $KDP are the primary beneficiaries, with recent price trends showing a broad market recovery rather than bill-specific movement.
Growing and Preserving Innovation in America Act of 2025
HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.
Rural Obstetrics Readiness Act
The Rural Obstetrics Readiness Act authorizes only $5M in grants over 3 years for rural obstetric emergency training and equipment. This is early-stage legislation (referred to committee, no appropriations) with near-zero market impact. The $5M authorization is approximately 0.0003% of Medtronic's annual revenue. Tickers are included only for completeness; the impact is structurally neutral.
Skinny Labels, Big Savings Act
The Skinny Labels, Big Savings Act (S.43) creates a statutory safe harbor protecting generic drug manufacturers from patent infringement lawsuits when they seek FDA approval for and market 'skinny label' generics. The bill is in early legislative stages (referred to Senate Judiciary Committee, January 2025). If enacted, it structurally favors generic manufacturers like Teva ($TEVA) and Viatris ($VTRS) by eliminating litigation risk, while negatively impacting brand-name drug companies whose multi-use patents will no longer block generic entry. Teva's stock has rallied 13.36% in 7 days and 24.8% in 30 days; Viatris gained 1.49% (7-day) and 15.51% (30-day), reflecting early market pricing of this regulatory catalyst.
More Homes on the Market Act
HR1340 (More Homes on the Market Act) proposes doubling the capital gains exclusion on home sales. If enacted, it would incentivize homeowners to sell, increasing housing inventory and transaction volumes. Real estate marketplace Zillow ($Z) and major mortgage lenders WFC, JPM, and BAC are structural beneficiaries.
Repeal Community Development Block Grants Act of 2025
HR1133 is an early-stage bill to eliminate the Community Development Block Grant program. Passage probability is very low given single sponsorship and no committee action since referral. Bearish for homebuilders reliant on subsidized infrastructure, but near-term market impact is negligible.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.